PMID- 10975472
OWN - NLM
STAT- MEDLINE
DCOM- 20001222
LR  - 20191104
IS  - 1091-6660 (Print)
IS  - 1091-6660 (Linking)
VI  - 4
IP  - 4
DP  - 2000 Aug
TI  - Recent advances of therapeutic apheresis in Guillain-Barre syndrome.
PG  - 271-4
AB  - Acute idiopathic demyelinating polyneuritis (AIDP), commonly known as the 
      Guillain-Barre syndrome (GBS), is an immune-mediated demyelinating disease of the 
      peripheral nerve and nerve roots. A number of immunological mechanisms were 
      described, but the exact pathomechanism has not been explained fully. Presumably, 
      a variety of immunological processes lead to a relatively uniform clinical 
      phenotype. Two large multicenter studies showed that plasma exchange (PE) was 
      significantly superior to supportive treatment only. Selective adsorption (SA) 
      also was employed as a method of therapeutic apheresis, and various smaller 
      studies established that both PE and SA are equally effective treatments for GBS. 
      Recently, it was demonstrated that the number of apheresis treatments should be 
      adapted to the severity of disease. A large multicenter controlled study 
      established equal efficacy of PE and intravenous immunoglobulin treatment (IVIg) 
      as well as the combination of PE and IVIg. Since that time, the use of apheresis 
      for the treatment of GBS declined in many countries due to the easier application 
      of IVIg. The number of patients treated in larger hospitals with long-standing 
      experience in the treatment of GBS also has declined.
FAU - Haupt, W F
AU  - Haupt WF
AD  - Department of Neurology, University of Cologne, Germany.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Ther Apher
JT  - Therapeutic apheresis : official journal of the International Society for 
      Apheresis and the Japanese Society for Apheresis
JID - 9706703
RN  - 0 (Immunoglobulins, Intravenous)
SB  - IM
MH  - *Blood Component Removal
MH  - Combined Modality Therapy
MH  - Guillain-Barre Syndrome/*therapy
MH  - Humans
MH  - Immunoglobulins, Intravenous/therapeutic use
MH  - Immunosorbent Techniques
MH  - Plasma Exchange
RF  - 16
EDAT- 2000/09/07 11:00
MHDA- 2001/02/28 10:01
CRDT- 2000/09/07 11:00
PHST- 2000/09/07 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2000/09/07 11:00 [entrez]
AID - 10.1046/j.1526-0968.2000.004004271.x [doi]
PST - ppublish
SO  - Ther Apher. 2000 Aug;4(4):271-4. doi: 10.1046/j.1526-0968.2000.004004271.x.